Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)

Phase 2MTX-463Positive

AI Analysis

Summary

Mediar Therapeutics completed enrollment of 168 patients in the Phase 2 WISPer trial of MTX-463, a first-in-class antibody targeting WISP-1, for idiopathic pulmonary fibrosis across 70+ global sites.

Clinical Trial Data

Phase

Phase 2

Patients

168

Outcome Details

Enrollment completed in Phase 2 WISPer trial

Importance:6/10

Sentiment:

0.60

Phase 2IPFFirst-in-classEnrollment completionGlobal study

Related Companies

$AAGH $GBCMD $TRAX

Read the original article

Published by PR Newswire Biotech on October 7, 2026 11:08 AM

Read Original